{"id":"W4401324671","doi":"10.3390/vaccines12080883","title":"Long-Term Safety and Immunogenicity of AZD1222 (ChAdOx1 nCoV-19): 2-Year Follow-Up from a Phase 3 Study","year":2024,"lang":"en","type":"article","venue":"Vaccines","topic":"SARS-CoV-2 and COVID-19 Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"National Institute of Allergy and Infectious Diseases; AstraZeneca","keywords":"Immunogenicity; Medicine; Vaccination; Placebo; Neutralizing antibody; Internal medicine; Antibody; Antibody titer; Coronavirus disease 2019 (COVID-19); Randomized controlled trial; Immunology; Titer; Infectious disease (medical specialty); Disease; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003802039,0.0002177697,0.0005073042,0.0003006808,0.00007239179,0.00005474994,0.000194464,0.00008498545,0.0001299204],"category_scores_gemma":[0.0002548768,0.0001714456,0.0001466825,0.0005862999,0.00002765284,0.00009871918,0.0002213474,0.0002302875,0.0001063048],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006956734,"about_ca_system_score_gemma":0.0001990377,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00133704,"about_ca_topic_score_gemma":0.0003755958,"domain_scores_codex":[0.9983039,0.00006951018,0.0004258909,0.0005056679,0.0003976586,0.0002973382],"domain_scores_gemma":[0.9989467,0.000243086,0.00004126691,0.0005418004,0.000132762,0.00009437554],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01188208,0.001363901,0.778245,0.0004795182,0.0009107521,0.0006898906,0.003656495,2.241883e-7,0.1750457,0.00003961939,0.001083657,0.02660313],"study_design_scores_gemma":[0.0463715,0.006829686,0.7625486,0.0009202115,0.001060293,0.0001112282,0.001889152,0.0004542694,0.1360827,0.0003012448,0.04266917,0.0007619062],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9937239,0.003858824,0.0001949827,0.0003893992,0.0003775257,0.0009808124,0.00009618911,0.0001159551,0.0002623959],"genre_scores_gemma":[0.9975473,0.00004352989,0.00007507145,0.001716134,0.0002942567,0.00003763835,0.00001363698,0.00004148034,0.0002309628],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04158551,"threshold_uncertainty_score":0.6991349,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03817204875476456,"score_gpt":0.3710456522787309,"score_spread":0.3328736035239664,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}